Prevention of Cardiovascular Disease in Women: Evidence for the Use of Hormone Replacement Therapy

1. 1997 Heart and Stroke Statistical Update. Dallas, Texas. American Heart Association 1997.

2. Lerner DJ Kannel WB . Patterns of coronary heart disease morbidity and mortality in the sexes: A 26 year follow-up of the Framingham population. Am Heart J 1986; 111: 383–390.

3. Collins P. Vascular aspects of oestrogen. Maturitas 1996; 23: 217–226.

4. Stamfer MJ Colditz GA . Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63.

5. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.

6. The Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494–502.

7. Scandinavain Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patinets with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

8. Lewis S Sacks F Mitchell J . Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140–146.

9. MacMahon S Peto R Cutler J . Blood pressure, stroke and coronary heart disease, part 1: effects of prolonged differences in blood pressure – evidence from nine prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765–774.

10. World Health Organization. Annual Report. Geneva: World Health Organisation, 1997.

11. Grodstein F Stampfer MJ Colditz GA . Post-menopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–1775.

12. Austin MA Hokanson JE Edwards KL . Hypertriglyceridemia as a cardiovascular risk factot. Am J Cardiol 1998; 81: 7B–12B.

13. Falkeborn M Persso I Adami HO . The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–828.

14. Stampfer MJ Colditz GA . Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63.

15. Grady D Rubin SM Petitti DB . Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Int Med 1993; 117: 1038–1041.

16. Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457–461.

17. The Writing Group for the PEPI Trial. Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Post-menopausal Women. The Post-menopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208.

18. Hulley S Grady D Bush T . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613.

19. Shlipak MG Simon JA Vittinghoff E . Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845–1852.

20. Simon JA Hsia J Cauley JA . Post-menopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103: 638–642.

21. Grodstein F Manson JE Colditz GA . A prospective, observational study of post-menopausal horomone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.

22. Herrington DM Reboussin DM Brosnihan B . Effects of estrogen replacement on the progression of coronary artery atherosclerosis. New Engl J Med 2000; 343: 522–529.

23. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials 1998; 19: 61–109.

24. National Institutes of Health, National Heart, Lung and Blood Institute. Women's Health Initiative. Available at: www.nhlbi.nih.gov/whi/hrt-en.htm

25. Vickers MR Meade TW Wilkes HC . Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995; 191: 150–154.

26. Shibata M Lees B Collins P . Prevention of cardiovascular disease in women: evidence for the use of hormone replacement therapy. J Br Meno Soc 2001; 1: 33–36.

27. Herrington DM Vittinghoff E Hunninghake D . Effects of statin therapy on cardiovascular events and all cause mortality in women in the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2000; A4024.

28. Mosca L. The role of Hormone Replacement Therapy in the prevention of post-menopausal heart disease. Arch Intern Med 2000; 160: 2263–2272.

29. Mosca L Collins P Herrington DM . Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American heart Association. Circulation 2001; 104: 499–503

30. Post W Goldschmidt-Clermont PJ Wilhide CC . Methylation of the estrogen receptor gene is associated with ageing and atherosclerosis in the cardiovascular system. Cardiovasc Res 1999; 43: 985–991.

31. Teede HJ Liang YL Shiel LM . Hormone replacement therapy in post-menopausal women protects against smoking induced changes in vascular structure and function. J Am Coll Cardiol 1999; 34: 131–137.

32. Rosano GMC Leonardo F Onorati D . Modifications in lipid profile and endothelial function in response to low dose estrogen replacement therapy in menopausal women at risk for CAD. Circulation 2000; 18: A3414.